Key facts
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2026, 21:55.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options Exercise
Tax liability
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Options Exercise
Additional SEC filing notes
Footnote F1
Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Footnote F2
The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.
Footnote F3
The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F4
Each RSU represents the contingent right to receive one share of the Issuer's common stock.
Footnote F5
On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.